2015
Intravenous Leiomyomatosis Revisited
Carr RJ, Hui P, Buza N. Intravenous Leiomyomatosis Revisited. International Journal Of Gynecological Pathology 2015, 34: 169-176. PMID: 25675187, DOI: 10.1097/pgp.0000000000000127.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisSmooth muscle originMuscle originCases of IVLCommon extrauterine siteRight heart chambersGood overall prognosisPatients' medical recordsDirect mass effectGross pathologic findingsConventional diagnostic criteriaExtrauterine extensionExtrauterine involvementClinical sequelaeOverall prognosisDisease recurrenceMedian agePatient agePrompt diagnosisInitial diagnosisPathologic findingsSignificant morbiditySurgical excisionInferior venaPrimary lesion
2014
Egg Donor Pregnancy
Buza N, Hui P. Egg Donor Pregnancy. International Journal Of Gynecological Pathology 2014, 33: 507-510. PMID: 25083967, DOI: 10.1097/pgp.0b013e3182a1028b.Peer-Reviewed Original ResearchConceptsDonor pregnanciesMedical recordsClinical gestational ageFirst case reportPatients' medical recordsPositive nuclear stainingNormal staining patternVillous stromal cellsMaternal decidual tissuesDNA genotypingChorionic villous tissueGestational ageUnderwent dilationCase reportUterine contentsVillous tissueMorphologic featuresStromal cellsPregnancyStaining patternComplete hydatidiformPartial hydatidiformChorionic villiNuclear stainingMicroscopic evaluation
2013
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 overexpressionEndometrial carcinomaMedical recordsImmunohistochemical scoreHER2 testingProtein expressionHER2 immunohistochemistrySignificant heterogeneityScoring systemMultiple tumor sectionsPure serous carcinomaHER2-positive casesHER2-positive tumorsScoring criteriaEndometrial carcinoma casesFDA criteriaPatients' medical recordsLarge academic centerHER2 FISH resultsHER2 protein overexpressionPromising therapeutic targetOverall concordance rateHER2 immunohistochemical scores